FDI IN PHARMA STAYS AT 100% BUT WITH CERTAIN RESTRICTIONS CURRENT (FIPB) & PROPOSED (CCI) APPROVAL REQUIREMENTS MAY ACT AS A SPEED BREAKER FOR POTENTIAL FOREIGN INVESTORS.

摘要

The pharma and healthcare sector in India has been benefiting from 100 per cent foreign direct investment (FDI) under the automatic route, i.e., without the need for approval of the Foreign Investment Promotion Board (FIPB). In recent times, however, certain ministries and nongovernmental organisations (NGOs) have recommended restricting FDI to 49 per cent in Indian Companies.